4BB 4basebio Plc

 
TIDM4BB 
 
03 April 2023 
 
                                 4basebio PLC 
 
                  ("4basebio", the "Company" or the "Group") 
 
         Signing of new lease and expansion of manufacturing capacity 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces a further expansion of its UK facilities. 
 
In light of the continued expansion of its commercial capabilities, 4BB is 
relocating its manufacturing and quality assurance teams to new premises 
adjacent to its existing clean room facilities.  Consequently, it has entered 
into a lease ("Lease") to rent the premises which provide dedicated laboratory, 
warehousing and office space for those teams. 
 
The additional property brings the overall footprint in the UK to 21,000 square 
feet and reflects the growth in the UK team to more than 60 staff today and 
provides room for further expansion. 
 
The Lease is for 13 years with an annual cost of approximately £9 per square 
foot and has been prepared on the basis of standard commercial terms. The 
property's ownership includes persons related to Heikki Lanckriet, the 
Company's CEO and CSO. 
 
Related Party Transaction 
 
As a result of the property, over which the Company has entered into the Lease, 
being part owned by persons related to a director, entering into the Lease by 
the Company constitutes a related party transaction ("Transaction") pursuant to 
the AIM Rules for Companies.  With the exception of Dr Lanckriet, the directors 
of the Company, having consulted with the Company's Nominated Adviser, Cairn 
Financial Advisers LLP, consider the terms of the Transaction to be fair and 
reasonable insofar as the Company's shareholders are concerned. 
 
Dr Heikki Lanckriet, CEO and CSO for 4basebio, commented: "The addition of the 
new premises locates the manufacturing and quality assurance teams alongside 
the company's clean rooms; moreover it will allow the company to continue 
expanding its commercial teams at its main facility, thereby accelerating the 
company's capacity to onboard new clients moving forward." 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the 
European Union (Withdrawal) Act 2018). 
 
For further enquiries, please contact: 
 
4basebio PLC                                             +44 (0)12 2396 7943 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated Adviser)         +44 (0)20 7213 0880 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker) 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe          +44 (0)20 7220 0500 
 
 
Notes to Editors 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for cell and gene therapies and DNA vaccines and providing solutions for 
effective and safe delivery of these DNA based products to patients. It is the 
intention of the Company to become a market leader in the manufacture and 
supply of high purity, synthetic DNA for research, therapeutic and 
pharmacological use and develop non-viral vectors for the efficient delivery of 
payloads. The immediate objectives of 4bb are to validate and scale its DNA 
synthesis and advance its collaborations to facilitate the functional 
validation of its DNA based products and cell and gene delivery solutions. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced 
by factors that could cause actual outcomes and results to be materially 
different. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

April 03, 2023 07:11 ET (11:11 GMT)

4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024

4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024